Brugada phenocopy (BrP) denotes reversible Brugada-type electrocardiogram changes from transient triggers, requiring management distinct from congenital Brugada syndrome. A 19-year-old man collapsed at home, regained consciousness in transit, and soon after emergency department arrival had recurrent syncope with ventricular fibrillation, which was defibrillated (200 J). The electrocardiogram showed PR interval approximately 200 milliseconds, QRS interval approximately 160 milliseconds, QTc interval approximately 489 milliseconds, lateral J-waves, and coved ST-segment elevation in V1-V2. A review of his phone confirmed propafenone ingestion (approximately 2.5 g over 3 days). Intravenous sodium bicarbonate led to rapid QRS interval narrowing and clinical stabilization. The triad of diffuse conduction delay, V1-V2 coved morphology, and J-waves in acidemia with dose-verified exposure supports drug-induced BrP. Early bicarbonate reverses sodium-channel blockade; normalization and normal cardiac magnetic resonance argue against a fixed substrate, so implantable cardioverter-defibrillator is unnecessary. BrP resolves after correcting reversible triggers. In sodium-channel blocker toxicity with QRS interval widening, early sodium bicarbonate is first-line therapy.
7 December 2025 in Catheterization and Cardiovascular Interventions
Background: Myocardial infarction with nonobstructive coronary arteries (MINOCA) is heterogeneous and increasingly recognized. Myocardial bridging (MB) may predispose to nonobstructive ischemia, yet the clinical relevance of serum magnesium in this phenotype is unclear. Objectives: To evaluate whether lower serum magnesium is independently associated with MINOCA among patients with angiographically confirmed MB without significant coronary atherosclerosis. Methods: We conducted a single‐center, retrospective study of consecutive adults undergoing coronary angiography (April 2020–June 2024). Among 25,240 angiograms, MB was identified in 2592 patients; after excluding obstructive stenosis and major comorbidities, 337 MB patients without significant atherosclerosis were included: 44 with MINOCA and 293 controls. Serum magnesium (first value within 24 h) was the exposure. Associations were estimated using Firth’s penalized logistic regression. Dose–response was examined with restricted cubic splines (RCSs); discrimination was assessed by receiver operating characteristic (ROC) analysis. Prespecified subgroup analyses tested for effect modification. Results: Patients with MINOCA had lower magnesium than controls (0.77 ± 0.07 vs. 0.92 ± 0.10 mmol/L). Each 0.1 mmol/L decrease in magnesium was associated with higher odds of MINOCA (adjusted odds ratios [ORs] ≈ 7.1, 95% confidence interval [CI] ≈ 4.0–14.3). RCS showed a near‐linear inverse relationship (P_overall < 0.001; P_nonlinear = 0.434), with risk increasing below ∼0.89 mmol/L (reference). Magnesium alone demonstrated excellent discrimination (area under the curve [AUC] 0.901); the Youden‐optimal threshold (0.855 mmol/L) yielded sensitivity of 88.6% and specificity of 74.4%. Findings were broadly consistent across subgroups (no significant interactions). Conclusions: In MB patients without significant atherosclerosis, lower serum magnesium is independently associated with MINOCA, with an approximately linear dose–response and strong discriminative performance.
17 March 2026 in Reviews in Cardiovascular Medicine
Coronary artery ectasia (CAE) is characterized by abnormal, localized, or diffuse dilatation of the coronary vasculature and is an increasingly recognized anatomical entity encountered during coronary angiography. Although often associated with atherosclerosis, the exact pathogenesis of CAE remains unknown; hence, an optimal management strategy is difficult to establish and remains highly controversial due to a lack of high-quality randomized controlled trial evidence. Current therapeutic modalities include medical therapy, percutaneous coronary intervention (PCI), and surgical options. We present a review, supported by a representative case of ST-elevation myocardial infarction (STEMI) in a patient with CAE, as a systematic summary of the clinical and angiographic features of the condition. We discuss contemporary treatment approaches, especially how to navigate antithrombotic strategies and the role of intravascular ultrasound (IVUS)-guided PCI.